Prognose

Das durchschnittliche Kursziel der Analysten beträgt +6,79€(−35,33%). Der Median liegt bei +6,79€(−35,33%).

Kaufen	3
Halten	1
Verkaufen	2

Scoring-Modelle

Dividenden-Strategie	0 / 15
HGI-Strategie	6 / 18
Levermann-Strategie	-2 / 13

News

Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors
Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeutics BOSTON , Jan. 13, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a research collaboration with Universal Cells, an Astellas company, to optimize next-generation induced pluripotent stem cell (iPSC)-derived cancer cell therapies. This collaboration underscores Ginkgo's capacity to deploy high-throughput biological approaches to tackle the complex challenge set associated with development of therapies targeting solid tumors.» Mehr auf prnewswire.com
Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery
The Truveta collaboration will extend Regeneron Genetics Center's ® (RGC TM ) world-leading DNA sequence-linked healthcare database (now including almost three million de-identified patient volunteers) through genetic sequencing of up to ten million additional patient volunteers, all with linked electronic health records, creating the Truveta Genome Project» Mehr auf globenewswire.com
Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates
- Signals Start of New Commercialization Phase for LineaRx Subsidiary - - Company Negotiating GMP Supply Agreement - - Company Reaffirms Strategic Restructuring Timeline - STONY BROOK, NY / ACCESSWIRE / January 10, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing facility (the "facility") within its Stony Brook, New York, headquarters and readiness to accept orders for the manufacture of LineaDNA™ IVT templates that clients can utilize for the production of mRNA clinical trial materials. The facility is undergoing final testing and is expected to be fully operational by the end of the current month.» Mehr auf accesswire.com

Unternehmenszahlen

Im letzten Quartal hatte Ginkgo Bioworks einen Umsatz von 79,96 Mio€ und ein Nettoeinkommen von −50,65 Mio€

(EUR)	Sep. 2024	YOY
Umsatz	+79,96 Mio	52,71%
Bruttoeinkommen	+70,99 Mio	54,94%
Nettoeinkommen	−50,65 Mio	82,30%
EBITDA	−32,26 Mio	77,40%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+603,48 Mio€
Anzahl Aktien	57,48 Mio
52 Wochen-Hoch/Tief	+62,43€ - +5,10€
Dividenden	Nein
Beta	1,1
KGV (PE Ratio)	−0,87
KGWV (PEG Ratio)	−0,02
KBV (PB Ratio)	+0,71
KUV (PS Ratio)	+2,86

Unternehmensprofil

Ginkgo Bioworks Holdings, Inc. entwickelt zusammen mit seinen Tochtergesellschaften eine Plattform für die Zellprogrammierung. Die Plattform wird zur Programmierung von Zellen verwendet, um die biologische Herstellung von Produkten wie neuartigen Therapeutika, Lebensmittelzutaten und aus Erdöl gewonnenen Chemikalien zu ermöglichen. Das Unternehmen bedient verschiedene Endmärkte, darunter Spezialchemikalien, Landwirtschaft, Lebensmittel, Konsumgüter und Pharmazeutika. Ginkgo Bioworks hat eine Partnerschaft mit Selecta Biosciences, Inc. zur Entwicklung der ImmTOR-Technologieplattform. Ginkgo Bioworks Holdings, Inc. wurde im Jahr 2008 gegründet und hat seinen Hauptsitz in Boston, Massachusetts.